Processing your payment...
Please do not close your browser.

Generic Injectables Market - Global Growth, Trends and Forecast (2022 - 2029) By Types, By Application, By Regions and By Key Players: Sandoz (Novartis) (SWX: NOVN), Hikma Pharmaceuticals PLC (LON: HIK), Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY)

27 Jun, 2022 | 156 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the next Forecast years the Oral Ulcer Drug market will register a 10.9% CAGR in terms of revenue, the global market size will reach USD 150.66 billion by 2029.

Generic Injectables Market Overview

Generic injectables are bioequivalents of branded injectables that are not covered by patents. Because they have the same active ingredient, dosage, strength, quality, and form as the innovative pharmaceuticals, they are just as safe and effective.

Governments in a number of nations are encouraging the production of generic injectables due to the benefits they provide. Furthermore, an increase in drug shortages, particularly in the United States, as well as the patent expiration of a number of blockbuster drugs, an ageing population, and the increased frequency of chronic and lifestyle diseases are some of the other reasons driving the market's expansion.

Furthermore, rising investment on R&D and new breakthroughs in generic medications, as well as increasing drug patent expiration, are all contributing to the market's growth Furthermore, the increased occurrence of acute and chronic illnesses like as diabetes and cancer, which require generic injectable medications, is related to the generic injectable market's growth. Furthermore, high production costs for generic injectable pharmaceuticals are expected to impede market expansion.

By 2031, the generic injectables industry is estimated to reach $307.7 billion. The Food and Drug Administration (FDA) in the United States has approved the first generic of glucagon for injection USP for the treatment of severe hypoglycemia in diabetic patients. In circumstances where decreased intestinal motility is beneficial, the medication offers potential as a diagnostic help in radiologic examinations of the stomach, duodenum, small bowel, and colon.

What is our Generic Injectables Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029 CAGR

 

CAGR of 10.9% during the review period (2022 to 2029).

 

By Type

  • Small Molecule
  • Large Molecule

 

By Application

  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases

 

 By Companies

 

 

 

 

Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma, Endo International PLC, Merck, Armas Pharmaceuticals Inc

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Base Year

 

 

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

156

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Who are the Major Players in Generic Injectables Market?

The Generic Injectables Market is growing at a very fast pace and has seen the focus of many local and regional vendors offering precise application products for multiple end users. The three dependencies for the status of major companies in the market are: company profile, profitable gross margin, the prices they charge. These are the main players in this market Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis) (SWX: NOVN), Hikma Pharmaceuticals PLC (LON: HIK), Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY), Grifols (BME: GRF), Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma, Endo International PLC Merck, Armas Pharmaceuticals Inc.

Industry News:

In January 2020, Merck collaborated with Taiho Pharmaceutical Co, Ltd. for oncology business to widen its focus on small molecule offerings in injection inhibitors for cancer research, thereby widening its business.

In May 2019, Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. company formed a strategic collaboration to multisource injectable products in the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, was introduced which was in drug shortage in the FDA Drug Shortage list since September of 2018.

What are the major Applications, Types and Regions for Generic Injectables Market?

By Type, it is segmented into

  • Small Molecule
  • Large Molecule

By Applications it is segmented into

  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases

Generic Injectables Market Regional Analysis

The second-most lucrative market for generic injectables is expected to be North America. This is due to a rise in the number of abbreviated new drug application (ANDA) approvals, increased demand for low-cost biosimilars, and the rising prevalence of lifestyle diseases.

The Asia Pacific area is the largest market for generic injectables, with China leading the way, followed by India. The increasing acceptance of new technologies, together with the rising population, and the introduction of favourable government regulations, are attributed to the growth of the generic injectables market in China. According to the National Health Commission (NHC), China has relied heavily on generic medications, with almost 95 percent of the 170,000 drug licences awarded by the China FDA being generics.

The market for Generic Injectables in Asia is predicted to increase rapidly over the next few years, followed by Europe. In Asia, China and India are likely to be the fastest expanding markets.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America

The Generic Injectables Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Generic Injectables Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
  4. Key Insights
    1. Pricing Analysis, By Key Regions, 2022
    2. Price Comparison (USD Per Ton) By Type (Small Molecule, Large Molecule) 2021/2022
    3. Price Comparison (USD, Per Ton): By Application (Oncology, Anesthesia, Anti-Infectives, Parenteral Nutrition, Cardiovascular Diseases) 2021/2022
    4. Impact of COVID-19 on the Generic Injectables Market
    5. Production Share of Generic Injectables, By Region, 2022
    6. Key Industry Developments
  5. Global Generic Injectables Market Analysis, Insights and Forecast, 2022-2029
    1. Market Analysis, Insights and Forecast – By Application
      1. Oncology
      2. Anesthesia
      3. Anti-Infectives
      4. Parenteral Nutrition
      5. Cardiovascular Diseases
    2. Market Analysis, Insights and Forecast – By Type
      1. Small Molecule
      2. Large Molecule
    3. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Rest of World
  6. Competitive Analysis
    1. Global Market Share Analysis (2021)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
      1. Sandoz (Novartis) (SWX: NOVN)
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Hikma Pharmaceuticals PLC (LON: HIK)
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY)
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Grifols (BME: GRF)
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla